Global Endo and Exo-Peptidases Market Size (2022 – 2030)

The Global Endo and Exo-Peptidases Market was valued at USD 1.02 billion and is projected to reach a market size of USD 1.5 billion by the end of 2030. Over the forecast period of 2023-2030, the market is projected to grow at a CAGR of 5%. 

Industry Overview

The peptide bonds within a polypeptide or protein are broken by the enzyme known as an endopeptidase. A proteolytic peptidase known as endopeptidase or endoproteinase breaks peptide bonds between nonterminal amino acids (i.e. within the molecule). A class of hydrolases known as endopeptidase hydrolyzes proteins by catalyzing the hydrolysis of peptidic linkages. Additionally, these enzymes exhibit high degrees of chemo-, regio-, and enantioselectivity and are active in mild reaction environments. Endopeptidase has historically been used in the food business (fabrication of cheese, quality improvement of bread, and preparation of soil proteins). Usually, it is particular to particular amino acids. Trypsin, chymotrypsin, elastase, thermolysin, pepsin, glutamyl endopeptidase, and neprilysin are a few examples of endopeptidases.

The primary factor fueling the market's expansion is the global population's increasing prevalence of diabetes, particularly type 2. More than 463 million people worldwide have diabetes in 2019, and the International Diabetes Federation (IDF) predicts that the number will rise over the predicted period. The dipeptidyl peptidase 4 (DPP-4) inhibitors support the body's release of insulin and control of blood sugar levels in patients. Therefore, during the forecast period, such factors are likely to accelerate market expansion. However, several adverse effects linked to the use of DPP-4 inhibitors as medications pose a threat to the market's expansion.

Impact of Covid-19 on the Industry

Endopeptidase demand is being hampered by the COVID-19 pandemic in various applications. Lockdowns have been enacted by governments in many different nations to stop the disease's spread. As a result, there have been bottlenecks in the infrastructure, limitations on supply and transportation, and occasional halts in production operations. The market for endopeptidase is being negatively impacted by this.

Tier I and tier II manufacturers and suppliers are the main players in the endopeptidase market. These players' manufacturing and supply chain facilities are dispersed among several nations in Asia Pacific, Europe, North America, Latin America, and the Middle East & Africa. The supply chain has seen a modest disturbance as a result of the industrial halt brought on by the COVID-19 outbreak. Nevertheless, a market recovery is anticipated soon.

Market Drivers

Advancements in medical technology will drive the market growth

The market for endopeptidase has grown as medical technology has developed because endopeptidase is employed in clinical pathology for diagnostic purposes. During the projected period, the demand for neprilysin is anticipated to increase in immunochemistry, lymphomas, leukemia, and veterinary medicine.

The rising demand for endopeptidases in the food industry will drive the market growth

During the projected period, the market is expected to grow as endopeptidase usage increases in the food industry. In the production of cheese and bread, endopeptidase is frequently utilized. Additionally, it is used in several food processing applications. The global endopeptidase market is being driven by the expansion of the food sector. Endopeptidase enzymes are an example of white/industrial biotechnology that enables the development of environmentally benign solutions for processing fibers in the textile industry.

Market Restraints

The rising trend of vegan consumption will challenge the market growth

The market for endopeptidases is projected to suffer from the rise of vegan dietary options. The development of new enzyme-based processes for a more ecologically friendly approach in the textile industry is made possible by advancements in enzymology, molecular biology, and screening methods. During the forecast period, the market is also anticipated to be constrained by this.

ENDO AND EXO-PEPTIDASES MARKET REPORT COVERAGE:

Global Endo and Exo-Peptidases Market- By Product Type

• Pepsin
• Trypsin
• Chymotrypsin
• Elastase

Based on product type, the global endo, and exo- peptidases market is segmented into pepsin, trypsin, chymotrypsin, and elastase. The pepsin segment is projected to grow with the highest CAGR during the period of analysis.

Global Endo and Exo-Peptidases Market- By Application

• Food
• Medicine
• Textile
• Fermentation
• Others

Based on Application, the global endo and exo-peptidases market are segmented into food, medicine, textile, and fermentation. The technological advancement in the medical segment is projected to drive the market growth and grow with the highest CAGR during the period of analysis.

Global Endo and Exo-Peptidases Market- By Geography & Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

In 2021, Europe held a disproportionate amount of market share due to the existence of significant producers there, including Novozymes, AB Enzymes, and DSM. The region's endopeptidase market is also being helped by the high endopeptidase consumption in food processing.

One of the main regions for endopeptidase consumption is the Asia Pacific. During the projected period, it is anticipated that the market in the area will grow more quickly than markets in other regions. During the projected period, the endopeptidase market in the Asia Pacific is anticipated to be driven by the expansion of the food and medical industries.

Global Endo and Exo-Peptidases Market- By Companies

• Novozymes
• DuPont
• AB Enzymes
• DSM
• Aum Enzymes
• BASF
• Chr.Hansen
• Kemin
• Yiduoli
• Sunhy Group

NOTABLE HAPPENINGS IN THE GLOBAL ENDO AND EXO-PEPTIDASES MARKET IN THE RECENT PAST:

• Merger & Acquisition: - In 2020, Novozymes adds a significant presence in the North American probiotics market with the acquisition of Microbiome Labs.
• Merger & Acquisition: - In 2020, Following the fulfillment of all closing conditions, Chr. Hansen Holding A/S ("Chr. Hansen") announced that the acquisition of UAS Laboratories LLC ("UAS Labs") had been completed.